Novo to count profit on one gulp with its new Wegovy™ Pill launch

Announcement

Novo Nordisk, the promising Danish healthcare organisation known for its excellent progress in diabetes care and later splitting its business and excellence in rare blood disorders, growth hormone therapies and obesity. The company has now launched Wegovy™ pill to be registered in the history of the healthcare sector as it’s the first oral GLP-1 alternative by the Food and Drug Administration for chronic weight management.

The oral formulation launch is a memorable milestone for the company in the extensive patient choice and reach to proof based obesity treatment. This new pill formulated option will open doors for revenue and strengthen recognition in the market.

New year, new launch

This launch is correlated and inspired by the famous NovoCare® experience, which was built on patients’ trust for the medication and understanding coverage alternatives. This was a switch for bolstering the ongoing contribution in their whole treatment procedure. Under this experience, the patients looking for ethical treatment with the FDA’s stamp on it involving Wegovy™ pill can now be equipped with the popular care providers that have the potential to provide a longitudinal, progressive and robust obesity care.

One of the NovoCare® providers, the Knownwell (company), takes the honour of being a part of this initiative. Knownwell is a metabolic and weight-based initial care health organisation serving in-person and virtual care to meet the convenience of the patient. This partnership between the two responsible companies, the patient group witnessing the new Wegovy™ pill, will directly get an insight into the Knownwell’s sincere, robust model that involves nutritional, behavioral and medical backup served smoothly via its national hybrid model.

Co-Founder and CEO of Knownwell, Brooke Boyarsky, said, “The access to the Wegovy pill marks a positive shift and a boon to obesity care that keeps choice, convenience and awareness at first place for the patients. We’re thrilled to have a ride of change with Novo’s new movement. This is a contribution to the patients who look for trustworthy and reliable treatment options, harnessed with quality insurance-covered care.”

Co-Founder and Chief Medical Officer of Knownwell, Dr Angela Fitch, said, “The pill is showing another way of benefits which patients can enjoy from an oral option. The innovative medications are coupled with education and continuous clinical care that further contribute largely to the patient's health and achieve good and positive sustainable healthcare results.”